0000000000757475

AUTHOR

Kerstin Schaefer-eckart

showing 6 related works from this author

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with ac…

2019

Background: Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. Methods: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland. Eligible patients were 18–70 years, had acute myeloid leukaemia in first or consecutive complete haematological remissi…

AdultMalemedicine.medical_specialtyTransplantation ConditioningPopulationMedizinAntineoplastic AgentsTreosulfanDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumanseducationBusulfanPreparative RegimenAgededucation.field_of_studybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedInterim analysis3. Good healthFludarabineTransplantationRegimenLeukemia Myeloid Acute030220 oncology & carcinogenesisMyelodysplastic SyndromesFemalebusinessBusulfanVidarabine030215 immunologymedicine.drug
researchProduct

Clinical Validation of a Novel Elispot-Based Diagnostic Assay: Monitoring Cytomegalovirus-Specific Cell-Mediated Immunity and Risk Stratification in …

2019

Increasing evidence suggests that impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause of uncontrolled CMV reactivations and associated complications in hematopoietic stem cell transplantation (HSCT). No reliable test exists to predict patients at risk of primary and/or recurrent CMV reactivations following HSCT. Accurately assessing CMV-CMI might therefore improve the risk stratification of patients and allow optimizing and individualizing patient care. This study aimed to evaluate the suitability of a novel IFN-γ ELISpot assay (T-Track® CMV), based on the stimulation of peripheral blood mononuclear cells with T-activated® pp65 and IE-1 CMV proteins, to…

OncologyTransplantationmedicine.medical_specialtybusiness.industryELISPOTmedicine.medical_treatmentHazard ratioCongenital cytomegalovirus infectionvirus diseasesHematopoietic stem cellHematologyHematopoietic stem cell transplantationmedicine.diseasePeripheral blood mononuclear cellReal-time polymerase chain reactionmedicine.anatomical_structureImmunityInternal medicinemedicinebusinessBiology of Blood and Marrow Transplantation
researchProduct

The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Anal…

2021

T-cell epitope matching according to the TCE3 algorithm classifies HLA-DPB1 mismatches in permissive and non-permissive. This classification has been shown to be predictive for mortality and acute GvHD (aGvHD) events in large international cohorts. We retrospectively genotyped HLA-DPB1 in 3523 patients transplanted in Germany between 2000 and 2014 and in their unrelated donors using an Illumina amplicon-NGS based assay. Aim of the study was to evaluate DP-compatibility beyond the established TCE3 algorithm by assessing the combined effect of several DP-mismatch parameters on post-transplant outcome. We implemented an extended DP-mismatch assessment model where TCE3, DP allotype expression w…

MalePermissivenessOncologyGraft vs host diseaseEpitopes T-LymphocyteGraft vs Host DiseaseKaplan-Meier Estimategraft-versus-host-disease0302 clinical medicineGermanyImmunology and AllergyChild3' Untranslated RegionsHLA-DP beta-ChainsBone Marrow TransplantationOriginal Research0303 health sciencesHistocompatibility TestingIncidenceStem cell transplantationMiddle AgedAllograftsAllotype3. Good healthHLA-DPB1Child PreschoolHistocompatibility030220 oncology & carcinogenesisFemaleUnrelated Donorslcsh:Immunologic diseases. AllergyAdultRiskmedicine.medical_specialtyAdolescentImmunologyGraft vs Leukemia EffectHuman leukocyte antigenPolymorphism Single Nucleotidestem cell transplantationRelapse free survivalLymphocyte DepletionYoung Adult03 medical and health sciencesInternal medicinemedicineHumansTransplantat-Wirt-Reaktionddc:610PermissivePeriphere StammzellentransplantationAllelesAgedRetrospective Studies030304 developmental biologyPeripheral Blood Stem Cell TransplantationHLA-DPB1Donor selectionbusiness.industryInfant NewbornModels ImmunologicalInfantmedicine.diseaseGraft-versus-host diseaseHLA-DPB1-permissivenessHLA-DPB1 expressionlcsh:RC581-607businessFrontiers in Immunology
researchProduct

Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic L…

2009

Abstract Abstract 3351 Poster Board III-239 Objectives: The majority of patients with chronic lymphocytic leukemia (CLL) who receive allogeneic hematopoietic cell transplantation (HCT) have fludarabine-refractory disease. The most active single agent in this disease stage is alemtuzumab. Alemtuzumab has a long half-life and induces profound T-cell depletion (TCD). Since TCD may mitigate graft-versus leukemia effects we evaluated „pre-conditioning“ with alemtuzumab followed by a washout period in order to minimize in vivo T-cell depletion of the graft in a phase II study (NCT 00337519). Methods: Patients received cytoreductive treatment with 3 × 30 mg alemtuzumab weekly prior to HCT. The sch…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGastroenterologySurgeryFludarabineTransplantationInterquartile rangeInternal medicinemedicineAlemtuzumabbusinessProgressive diseaseBusulfanmedicine.drugBlood
researchProduct

Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT

2021

Abstract Introduction: A common genetic variant within the TCRA-TCRD locus has been recently identified as a predictive factor of thymic function and T cell repertoire diversity (Clave et al., 2018). Specifically it was shown in a mouse model that transplantation of rs2204985 AA human hematopoietic stem cells (HSC) into immunodeficient mice led to lower thymocyte counts and poorer TCR diversity. T cell mediated pathways are known to play a significant role in immunological processes affecting HSCT outcome like GvL, GvH and infection. Aim of this study was to investigate the potential impact of donor rs2204985 genotype on patient's outcome after unrelated HSCT. Methods: The study included 2,…

Oncology0303 health sciencesmedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyHuman leukocyte antigenBiochemistryOutcome (game theory)3. Good health03 medical and health sciences0302 clinical medicineInternal medicinemedicinebusiness030304 developmental biology030215 immunologyBlood
researchProduct

Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation.

2016

Major histocompatibility complex class I polypeptide-related sequence A (MICA) is a highly polymorphic ligand of the activating NKG2D receptor on natural killer (NK) cells, γδ-T cells, and NKT cells. MICA incompatibilities have been associated with an increased graft-versus-host disease (GVHD) incidence, and the MICA-129 (met/val) dimorphism has been shown to influence NKG2D signaling in unrelated hematopoietic stem cell transplantation (uHSCT). We investigated the effect of MICA matching on survival after uHSCT. We sequenced 2172 patients and their respective donors for MICA. All patients and donors were high-resolution HLA-typed and matched for 10/10 (n = 1379), 9/10 (n = 636), or 8/10 (n…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyHematopoietic stem cell transplantationHuman leukocyte antigenMajor histocompatibility complexBiochemistryGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineMinor histocompatibility antigenHumansAgedPolymorphism GeneticbiologyDonor selectionbusiness.industryHistocompatibility TestingHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle AgedNKG2DNatural killer T cellSurvival AnalysisTissue DonorsSurgeryTransplantationstomatognathic diseases030104 developmental biologyGenetic LociMultivariate Analysisbiology.proteinFemalebusiness030215 immunologyBlood
researchProduct